Studying cancer drug effectiveness and safety in elderly patients
Official title: Population Pharmacokinetics, Effectiveness and Safety of Antineoplastic Drugs in Elderly Patients
Run by Shandong University · NCT05467189 · Data updated 2026-11-12
This study is testing how well and safely different cancer drugs work for older patients aged 65 and up to help improve their treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 65 Years to 100 Years |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Shandong University Academic / other |
| Drugs / interventions | Afatinib, Ceritinib, Crizotinib, Imatinib, Lapatinib |
| Locations | 1 site (Jinan, Shandong) |
| Status | Recruiting |
| Started | January 1, 2021 |
| Main results expected | March 30, 2028 |
| Study ends | June 30, 2028 |
| Registry record updated | July 20, 2022 |
| Trial ID | NCT05467189 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are elderly patients aged 65 and older who have been diagnosed with cancer and are currently using antineoplastic drugs.
✕Probably not a fit
Patients who are expected to die within 48 hours or have allergies to antineoplastic drugs will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to investigate the population pharmacokinetics, effectiveness, and safety of various antineoplastic drugs, including Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib, Imatinib, and Lapatinib, specifically in elderly patients aged 65 and older diagnosed with cancer. The study will analyze how these drugs behave in this population and recommend optimized dosage regimens to enhance treatment outcomes. By focusing on the elderly, the study addresses a critical gap in cancer treatment, as this demographic often responds differently to medications compared to younger patients.
Why it matters
Potential benefit: If successful, this study could lead to more effective and safer cancer treatments tailored for elderly patients.
How similar studies have gone: While there is ongoing research into cancer treatments for the elderly, this specific focus on population pharmacokinetics and optimized dosing regimens for a range of antineoplastic drugs is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Subjects must meet all of the following inclusion criteria to be enrolled in the study: 1. Age ≥65 years old; 2. Diagnosed with cancer; 3. Using antineoplastic drugs for treatment. Exclusion Criteria: Subjects with any of the following criteria will not be enrolled in this study: 1. Patients who are expected to die within 48 hours; 2. Patients with allergy to antineoplastic drugs; 3. Patients receiving other investigational drugs; 4. Other factors that the researcher considers unsuitable for inclusion.
Where it's running
-
Shandong Provincial Qianfoshan Hospital
Jinan, Shandong, China Recruiting
Study contacts
- Study coordinator: Zhao Wei, Ph.D
- Email: zhao4wei2@hotmail.com
- Phone: 86053188383308
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy
This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.